VTRS vs PFE

For growth investors, Pfizer Inc.

(PFE) is the stronger pick with -1. 6% revenue growth year-over-year, versus -3. 0% for Viatris Inc. (VTRS). Pfizer Inc. (PFE) offers the better valuation at 19. 5x trailing P/E (8. 9x forward), making it the more compelling value choice. Analysts rate Viatris Inc. (VTRS) a "Hold" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Viatris Inc.

is actually cheaper at 7. 1x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Viatris Inc.

(VTRS) delivered a total return of +40. 3%, compared to -13. 3% for Pfizer Inc. (PFE). Over 10 years, the gap is even starker: PFE returned +29. 6% versus VTRS's -51. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Pfizer Inc.

(PFE) is the lower-risk stock at 0. 54β versus Viatris Inc. 's 0. 99β — meaning VTRS is approximately 83% more volatile than PFE relative to the S&P 500. On balance sheet safety, Pfizer Inc. (PFE) carries a lower debt/equity ratio of 78% versus 100% for Viatris Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Pfizer Inc.

(PFE) is pulling ahead at -1. 6% versus -3. 0% for Viatris Inc. (VTRS). On earnings-per-share growth, the picture is similar: Pfizer Inc. grew EPS -3. 5% year-over-year, compared to -466. 0% for Viatris Inc.. Over a 3-year CAGR, VTRS leads at -4. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Pfizer Inc.

(PFE) is the more profitable company, earning 12. 4% net margin versus -24. 6% for Viatris Inc. — meaning it keeps 12. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PFE leads at 24. 7% versus -18. 6% for VTRS. At the gross margin level — before operating expenses — PFE leads at 70. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Viatris Inc.

(VTRS) trades at 7. 1x forward P/E versus 8. 9x for Pfizer Inc. — 1. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PFE: 3. 0% to $27. 27.

All stocks in this comparison pay dividends.

Pfizer Inc. (PFE) offers the highest yield at 6. 5%, versus 2. 8% for Viatris Inc. (VTRS).

For long-horizon retirement investors, Pfizer Inc.

(PFE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 54), 6. 5% yield). Both have compounded well over 10 years (PFE: +29. 6%, VTRS: -51. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: VTRS is a mid-cap quality compounder stock; PFE is a mid-cap income-oriented stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.